Dosage Forms

The NexGen Press 45 is the latest member of GEA Pharma & Healthcare’s NexGen Press line of tablet presses.

STADA and Alvotech have launched Uzpruvo in Europe, making it the first approved biosimilar to Stelara (ustekinumab) in the European market.

Pelletization, a popular oral drug delivery method in pharmaceuticals and nutraceuticals, offers numerous benefits. This article delves into the critical parameters for formulation development and technological consideration in pelletization, elucidating its significance in advancing pharmaceutical solutions.

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

Biosimilar analytical assessments focus on demonstrating biosimilarity and interchangeability with the reference biologic.

A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.

Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles.

Packaging and packaging line innovations are addressing the industry’s growing use of biologics.

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.

Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.

Looking at the role that RSV and pediatric medical practices play in drug shortages.

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.

The European Commission has granted approval for Tyruko (natalizumab), a biosimilar developed by Polpharma Biologics for treating multiple sclerosis.

Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.

European vaccine manufacturing is being boosted with high level investments.

Experts discuss the promise of personalized cancer vaccines through the inherent nimbleness of mRNA platform.

A comprehensive understanding of what makes mRNA vaccines tick is crucial in charting the future of the market.

Current good manufacturing practices for oral solid dosage forms protect the product from contamination and potential errors.

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

When evaluating a drug’s risk assessment for elemental impurities, one must consider all aspects of its lifecycle.